Sawhney RS, et al. (2004) Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells. J Biol Chem 279, 47379-90 15304500

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase

T412-p - p70S6K (human) ▲

Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene Orthologous residues p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes U0126 decrease EGF increase rapamycin EGF inhibit treatment-induced increase bisindolylmaleimide EGF inhibit treatment-induced increase rapamycin decrease bisindolylmaleimide no change compared to control

S434-p - p70S6K (human) ▲

Modsite: sFEPKIRsPRRFIGs SwissProt Entrez-Gene Orthologous residues p70S6K (human): S434‑p, p70S6K iso2 (human): S411‑p, p70S6K (mouse): S434‑p, p70S6K (rat): S434‑p, p70S6K iso2 (rat): S411‑p, p70S6K (fruit fly): S418‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase PD98059 EGF inhibit treatment-induced increase U0126 EGF inhibit treatment-induced increase rapamycin EGF inhibit treatment-induced increase bisindolylmaleimide EGF inhibit treatment-induced increase PD98059 no change compared to control U0126 no change compared to control rapamycin no change compared to control bisindolylmaleimide no change compared to control

T444-p - p70S6K (human) ▲

Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene Orthologous residues p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase U0126 EGF inhibit treatment-induced increase PD98059 EGF inhibit treatment-induced increase rapamycin EGF inhibit treatment-induced increase bisindolylmaleimide EGF inhibit treatment-induced increase U0126 no change compared to control rapamycin decrease bisindolylmaleimide decrease

S447-p - p70S6K (human) ▲

Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene Orthologous residues p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  colorectal cancer, colorectal carcinoma Relevant cell lines - cell types - tissues:  HCT116 (intestinal) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase U0126 EGF inhibit treatment-induced increase PD98059 EGF inhibit treatment-induced increase rapamycin EGF inhibit treatment-induced increase bisindolylmaleimide EGF inhibit treatment-induced increase U0126 no change compared to control rapamycin decrease bisindolylmaleimide decrease